<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910438</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12400 DepIST-H</org_study_id>
    <nct_id>NCT04910438</nct_id>
  </id_info>
  <brief_title>Prevalence and Longitudinal Follow-up of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo.</brief_title>
  <acronym>DepIST-H</acronym>
  <official_title>Prevalence and Longitudinal Follow-up Over 2 Years of Anal Lesions, HPV Infection and Associated Sexually Transmitted Infections Among Men Who Have Sex With Men (MSM) in Lomé, Togo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Lomé, Département de Santé Publique, Lomé, Togo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bichat Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Espoir Vie-Togo - ONG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Africain de Recherche en Epidémiologie et en Santé Publique, Lomé, Togo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire de Biologie Moléculaire et d'Immunologie, Lomé, Togo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint-Louis Hospital, Paris, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DepIST-H study, funded by the French AIDS and Hepatitis Research Agency (ANRS), is to&#xD;
      estimate prevalence (the number of cases over a given period of time) and incidence (the&#xD;
      number of new cases over a given period of time) of anal lesions (condylomas, dysplasia,&#xD;
      cancers) by HIV status among MSM in Lomé, Togo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: Prevalence and longitudinal follow-up over 2 years of anal lesions, HPV infection and&#xD;
      associated sexually transmitted infections among men who have sex with men (MSM) in Lomé,&#xD;
      Togo (ANRS12400 DepIST-H)&#xD;
&#xD;
      Main objective: To estimate the prevalence and incidence of anal lesions (condyloma,&#xD;
      dysplasia and anal cancers) according to HIV status among MSM in Lomé, Togo&#xD;
&#xD;
      Specific objectives :&#xD;
&#xD;
      To estimate the prevalence of HPV infection at baseline (M0) at anal and oropharyngeal sites&#xD;
      To describe the persistence of HPV infection at Year 1 and 2 at the anal and oropharyngeal&#xD;
      sites To describe the recurrence of anal lesions at Year 1 and 2 To estimate prevalence and&#xD;
      incidence of associated STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex&#xD;
      Virus type 2, Mycoplasma genitalium, Trichomonas vaginalis) HBV, HCV and syphilis&#xD;
&#xD;
      Methods :&#xD;
&#xD;
      This study is a prospective cohort with a 2-year follow-up of 200 MSM in Lomé (100 HIV- and&#xD;
      100 HIV+). Three data collection systems are integrated into the cohort: (i) clinical data,&#xD;
      (ii) socio-behavioural questionnaires, and (iii) biological data.&#xD;
&#xD;
      Sample size: 200 participants (100 HIV+ and 100 HIV-)&#xD;
&#xD;
      Interventions :&#xD;
&#xD;
      Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria&#xD;
      gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and&#xD;
      HBV).&#xD;
&#xD;
      Offering comprehensive care including prevention strategies adapted to the various STIs&#xD;
      mentioned above and their complications, particularly the progression to anal cancer for HPV&#xD;
      infections in MSM.&#xD;
&#xD;
      Statistical analysis methods :&#xD;
&#xD;
      Use of mixed approaches. For quantitative indicators, descriptive analysis techniques,&#xD;
      bivariate analysis (Student t test or Wilcoxon test for quantitative variables, Chi² or&#xD;
      Fisher test for categorical variables) and multivariate analysis (logistic regression).&#xD;
&#xD;
      To estimate the incidence if the STIs, Kaplan-Meier curves, Cox models analyses will be&#xD;
      conducted.&#xD;
&#xD;
      As the cohort is open and non-randomized, preliminary analyses will be conducted during the&#xD;
      collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence at inclusion of anal lesions</measure>
    <time_frame>at Day 0</time_frame>
    <description>According to HIV status among MSM in Lomé, Togo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of anal lesions at baseline</measure>
    <time_frame>at Day 0</time_frame>
    <description>According to HIV status among MSM in Lomé, Togo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anal lesions</measure>
    <time_frame>at 12 month and 24 month</time_frame>
    <description>According to HIV status among MSM in Lomé, Togo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the number of worsening events of anal cytological lesions</measure>
    <time_frame>at 12 month and 24 month</time_frame>
    <description>According to HIV status among MSM in Lomé, Togo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the proportion of recurrence of anal lesions</measure>
    <time_frame>at 12 month and 24 month</time_frame>
    <description>According to HIV status among MSM who received available treatment, in Lomé, Togo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of HPV infections</measure>
    <time_frame>at Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HPV infection</measure>
    <time_frame>at 12 month and 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the proportion of persistent HPV infections</measure>
    <time_frame>at 12 month and 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the proportion of clearance of HPV infections</measure>
    <time_frame>at 12 month and 24 month</time_frame>
    <description>in the same individual, on anal and oral specimens, based on HIV status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Prevalence of others STIs : N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis, Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C</measure>
    <time_frame>At Day 0, at 12 month and 24 month</time_frame>
    <description>According to HIV status</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of others STIs : Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis and Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C</measure>
    <time_frame>At Day 0, at 12 month and 24 month</time_frame>
    <description>According to HIV status</description>
  </other_outcome>
  <other_outcome>
    <measure>Determination of different Chlamydia trachomatis strains</measure>
    <time_frame>At Day 0</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Determination of antibiotic resistance profiles for Neisseria gonorrhoeae, Mycoplasma genitalium and Chlamydia trachomatis</measure>
    <time_frame>At Day 0</time_frame>
    <description>According to HIV status</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of HIV</measure>
    <time_frame>at 12 month and 24 month</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Papillomavirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STIs screening and care</intervention_name>
    <description>Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).&#xD;
Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, Blood Anal smear pharyngeal and oral specimens urethral specimens Swab of herpes&#xD;
      vesicles&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male who have sex with men living with HIV or not&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Being a male aged 18 or over&#xD;
&#xD;
          -  Self-reporting as being a MSM&#xD;
&#xD;
          -  Wishing to be part of a regular clinical follow-up&#xD;
&#xD;
          -  Agreeing to participate in the study and signing the informed consent form&#xD;
&#xD;
          -  Live in Lomé&#xD;
&#xD;
          -  Having had anal intercourse within the past six months prior to inclusion visit&#xD;
&#xD;
          -  Regardless of HIV status (infected or not)&#xD;
&#xD;
          -  Whether or not the participant has already taken antiretrovirals&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another biomedical and/or behavioural study on HIV, viral hepatitis&#xD;
             or sexually transmitted infections (CohMSM ANRS 12324-EF cohort of Lomé)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte Charpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Bichat Claude Bernard, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier Ekouevi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lomé University, Togo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Didier Koumavi Ekouevi</last_name>
    <phone>+228 99 68 67 35</phone>
    <email>didier.ekouevi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnold Sadio</last_name>
    <email>sadioarnold@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ONG, Espoir Vie Togo</name>
      <address>
        <city>Lomé</city>
        <country>Togo</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ephrem Mensah, MD</last_name>
      <phone>+228 90 01 64 11</phone>
      <email>ephremensah@hotmail.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>Togo</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>HIV</keyword>
  <keyword>MSM</keyword>
  <keyword>Togo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

